These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20398862)

  • 1. Transplant coronary artery disease.
    Zimmer RJ; Lee MS
    JACC Cardiovasc Interv; 2010 Apr; 3(4):367-77. PubMed ID: 20398862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac allograft vasculopathy.
    Lee MS; Finch W; Weisz G; Kirtane AJ
    Rev Cardiovasc Med; 2011; 12(3):143-52. PubMed ID: 22080925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of percutaneous coronary intervention in transplant coronary artery disease in pediatric heart transplant recipients.
    Lee MS; Sachdeva R; Kim MH; Sachdeva R
    J Invasive Cardiol; 2012 Jun; 24(6):278-81. PubMed ID: 22684382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary intervention.
    Lee MS; Cheng RK; Kandzari DE; Kirtane AJ
    Am J Cardiol; 2012 Jun; 109(12):1729-32. PubMed ID: 22465319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stent implantation for the treatment of cardiac transplant vasculopathy: the jury is still out.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):970-1. PubMed ID: 21598349
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent thrombosis--risk assessment and prevention.
    Motovska Z; Knot J; Widimsky P
    Cardiovasc Ther; 2010 Oct; 28(5):e92-100. PubMed ID: 20553282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevo stent: a successful stent makeover.
    Belardi JA
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):52-3. PubMed ID: 21181969
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.